Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Next Previous
Trial Profile

A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole lauroxil (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Alkermes plc

Most Recent Events

  • 11 Jun 2018 Outcomes of a PopPK model using data from 4 phase 1 studies including this study (ALK9072-A105) assessing simulations of Aripiprazole for a 1 day initiation regimen for the long acting antipsychotic aripiprazole lauroxil, published in the European Journal of Drug Metabolism and Pharmacokinetics.
  • 06 Jun 2017 According to an Alkermes media release, that the US FDA has approved two-month ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
  • 20 Mar 2017 According to an Alkermes media release, a supplemental New Drug Application (sNDA) for the two-month dosing option of ARISTADA is currently under review with the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top